Pathology Results Best Indicate the Course of Breast Cancer

A large proportion of all breast cancers (%89) present at early or locally advanced stages. In early-stage breast cancer, our treatment goals are to completely cure the cancer, reduce the likelihood of cancer recurrence and improve quality of life . Some of our patients with breast cancer need chemotherapy before surgery. This chemotherapy is called neoadjuvant chemotherapy. Its purpose is to shrink the tumor, make it suitable for surgery and improve treatment success. As the tumor shrinks, the success of breast-conserving surgery increases; response to treatment in the axillary lymph nodes will also reduce the likelihood of arm swelling after surgery.
What Is Pathological Complete Response?
The result showing how effective preoperative chemotherapy has been is the pathology result from breast cancer surgery. If no cancer cells are found in the surgical pathology after neoadjuvant treatment, we call this pathological complete response . We knew from previous studies that our patients achieving pathological complete response had a lower likelihood of cancer recurrence. Demonstrating this once again, approximately 28 thousand patients were included in 52 clinical studies, whose meta-analysis was presented at the 2018 San Antonio Breast Cancer Symposium.
What Is a Meta-Analysis? A meta-analysis is a comprehensive investigation combining the results of multiple independent studies on a particular topic and statistically analyzing their findings. Meta-analysis results are the strongest scientific evidence.
According to this comprehensive analysis, breast cancer patients achieving pathological complete response were shown to have a %69 lower cancer recurrence rate. The patients benefiting mostwere those with the breast cancer types triple-negative and HER2-positive breast cancer. In addition, patients deriving complete benefit had a %78 lower mortality (death) rate.

In the figure above, you can see how much higher the 5-year overall and event-free survival rates were in patients achieving pathological complete response compared with those with residual disease after surgery.
Conclusion
This study demonstrated the importance of neoadjuvant chemotherapy, particularly in triple-negative and HER2-positive breast cancer. Although it is a valuable study showing the contribution of pathological complete response to our patients, the different chemotherapy drugs used in patients are a limitation of the analysis. We will need to wait for publication of the study article for more detailed information.
Sources
Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients.
2018 San Antonio Breast Cancer Symposium, Abstract GS2-03.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.